All In Biotech

Drug Trial Radar · NCT06088004

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics (PK/PD) and Preliminary Efficacy of ABO2011 Monotherapy or in Combination With Toripalimab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Sep 28, 2023

Primary completion

Dec 30, 2026

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Abogen Life Sciences (Shanghai) Co., Ltd.
First posted
Oct 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

  • ABO2011 InjectionDrug

    Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection

  • ToripalimabDrug

    Anti-PD-1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Incidence and character of DLTsTime frame: monotherapy: 21 days after the first dose. Combination therapy: 28 days after the first dose]
  2. Phase I: Incidence of Adverse Event (AE)Time frame: monotherapy: from informed consent until 28 days after the last administration. Combination therapy: from informed consent until 90 days after the last administration.
  3. Phase I: Incidence of Serious Adverse Event (SAE)Time frame: monotherapy: from informed consent until 28 days after the last administration. Combination therapy: from informed consent until 90 days after the last administration.]
  4. Phase I: Incidence of patients with clinically significant abnormal laboratory resultsTime frame: monotherapy: from the first dose until 28 days of last administration. Combination therapy: from informed consent until 90 days after the last administration.
  5. Phase II: Objective response ratesTime frame: Estimated to be from time of informed consent up to 2 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, China · Recruiting

  • Shanxi Cancer hospital

    Shanxi, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

    Shenzhen, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.